Nippon Boehringer Ingelheim

CompanyJapan

Nippon Boehringer Ingelheim develops one asset. Mostly small molecule acting on ERBB2; based in Japan.

1
Asset
Furthest stage
Not known
0
Trials
1
Signal

Pipeline

1
  • Hernexeos

    Inhibits HER2 signaling to suppress growth of HER2-mutant cancer cells.

    Stage not known, Small molecule, ERBB2

Full company profiles: pipeline, trials, funding and people.

See Pro

In the full profile

  • Evidence behind the mechanisms1
  • Signals1
  • Integrity notices1
  • Similar companies3

Intelligence